News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1

ImmunityBio Shares Swoon After Merger https://labusinessjournal.com/news/2021/jul/26/immunitybio-shares-swoon-after-merger/

Gespräche und Anträge über die Anktiva Zulassung durch die FDA sollen auch noch dieses Jahr begonnen/eingereicht werden.

"The company expects to compile sufficient data for a BLA for their bladder cancer program this year (Figure 16). The company’s Phase III lung cancer and Phase III pancreatic cancer programs are not too far behind. Add in the potential of the COVID-19 vaccine candidate and ImmunityBio could be pulling in a significant amount of revenue in the coming years. That revenue should grow substantially in the following years as more and more programs make it through the FDA and ImmunityBio’s agents become a mainstay in oncology and infectious disease."

https://seekingalpha.com/article/4439819-immunitybio-market-has-lost-contact-following-merger

The Phase 1/2/3 trial will study the efficacy, safety, and immunogenicity of ImmunityBio’s T-Cell COVID-19 vaccine as a boost in participants who have already received a spike-only antibody-based vaccine The study is designed to explore whether the T-cell-based vaccine could prevent breakthrough infections from the Delta variant in health care workers who are already vaccinated Goal of the second-generation hAd5 S+N T-Cell COVID-19 vaccine is to potentially provide increased protection and long-term immunity against the multiple variants and third wave infections currently affecting South Africa and other countries Phase 1 studies of subcutaneous dosing in the US have demonstrated no serious adverse events and potent T-cell responses after a single prime dose

ImmunityBio Announces Authorization to Proceed with Phase 1/2/3 Randomized Trial in South Africa of Their Dual-Antigen T-Cell Vaccine as a Universal Boost in Previously Vaccinated Participants Against COVID-19 https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-authorization-proceed-phase-123-randomized?field_nir_news_date_value[min]=

Damit haben institutionelle Anleger ihren Anteil von knapp über 7% verdoppelt auf 14,6%. Wenn das nicht mal ein gutes Zeichen ist.

Sehr cool, danke👍

https://finance.yahoo.com/quote/IBRX/holders?p=IBRX&guccounter=1&guce_referrer=aHR0cHM6Ly9zdG9ja3R3aXRzLmNvbS8&guce_referrer_sig=AQAAAHMx6sTpZoQNMjXcCcMCm7o6FiEvss2KhPqODbcdB9xvwN-IhTbuWx0X-p00qSJIzMN84rxwPiEcXvyOUdnpNIsfxG1iLCxuBmD7ttgBt-cgVPqb0B1F5X7WHwz6oxegy4D7b5Crwg-czZPOk8_dqcs0HWeqxRguOTPKClskMHbI

The firm acquired 347,009 shares of the company’s stock, valued at approximately $8,238,000. ImmunityBio accounts for 1.1% of HarbourVest Partners LLC’s portfolio, making the stock its 13th biggest position. Several other hedge funds and other institutional investors BlackRock Inc. acquired a new position in first quarter valued at approximately $84,365,000. Geode Capital Management LLC acquired a new position in first quarter worth approximately $15,776,000. JPMorgan Chase & Co. acquired a new position in the first quarter worth approximately $12,908,000. Rafferty Asset Management LLC acquired a new position in the first quarter worth approximately $12,470,000. Finally, Northern Trust Corp acquired a new position in first quarter worth approximately $11,439,000. Institutional investors and hedge funds own 14.60% of the company’s stock.

Jhankster60 auf Stocktwits: Just a matter of time before IBRX takes off. PSS needs a revenue stream. immunitybio.com/immunitybio... “The high rates of progression and recurrence for NMIBC make it one of the most expensive cancers to treat. This preliminary data is heartening and provides additional evidence of the potential for ImmunityBio’s Anktiva in treating a serious and potentially fatal cancer, for which the alternative is a highly invasive radical cystectomy,” said Patrick Soon-Shiong, M.D., Chairman and CEO of ImmunityBio. “We expect to file a Biologics License Application following a meeting with the FDA in 2021.”

Von "Diefreeandsell" auf Stocktwits: "got a response from Sarah: We will report any activity related to our “At-the-Market” (ATM) offering in our quarterly SEC filings as required in the ordinary course of business. Our Q2 filling will be available in August. the ATM effectively provides a facility to raise incremental equity capital over time up to $500 million (i.e. there is no guarantee that all the ATM will be raised, …. Regarding research analysts, we’re actively talking with several sell-side analysts, including Jefferies, with the goal of securing additional coverage of the company in the coming months. Lastly, Dr. Soon-Shiong believes boosting an RNA vaccine with a DNA-based one like our hAd5 S+N could confer long-term immune memory. To this end, we are actively working on boost trials in the US and South Africa and will provide details when they are available. The Amyris deal is with Nant South Africa, which is a separate entity that is not related to ImmunityBio."

Dr. Pat Soon-Shiong @DrPatSoonShiong 6 hours ago: "RNA plus DNA is the way to go ! Antibodies plus T cells. We plan to prove this and take down the #DeltaPlusVariant" 🌋🌋🌋

ImmunityBio, Inc. @ImmunityBio vor 4 Std.: "We've announced the publication of a paper in the JITC about a proprietary method for identifying tumor-specific immunogenic targets in individual breast cancer patients. This can enable clinicians to choose the best therapy available today."

ImmunityBio and NantOmics Announce Clinical Validation of a Proprietary Method to Identify Unique Targets for Immunotherapy in Individual Breast Cancer Patients https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-and-nantomics-announce-clinical-validation?field_nir_news_date_value[min]=

FDA Authorizes ImmunityBio Study of Anktiva and PD-L1 t-haNK to Increase Effectiveness of Trodelvy in Triple-Negative Breast Cancer Open-label Phase 1b/2 study will evaluate the safety and preliminary efficacy of Anktiva (N-803) and PD-L1 t-haNK in combination with antibody-drug conjugate Trodelvy and low-dose chemotherapy in subjects with advanced triple-negative breast cancer (TNBC) after prior therapy The FDA approved Trodelvy for TNBC in April 2020 based on an overall response rate of 33.3%, with a median duration of response of 7.7 months; 55.6% maintained their response for 6 or more months and 16.7% maintained their response for 12 or more months. Study design is based on results of Phase 1 trial of haNK cells combined with Anktiva and low dose chemo in refractory triple negative breast cancer, where disease control rate of 78% and overall response rate of 67% was reached Enrollment expected to begin in Q3 2021 https://ir.immunitybio.com/news-releases/news-release-details/fda-authorizes-immunitybio-study-anktiva-and-pd-l1-t-hank?field_nir_news_date_value[min]=